As GLP-1 and specialty-drug utilization expands, SHARx warns employers that spending control needs forecasting, access strategies and total-spend discipline, not rebate guarantees alone.
As prescription spending continues to squeeze benefits budgets, SHARx says employers should measure the consequences in compensation, hiring, retention, and employee trust, not pharmacy costs alone.
Federal efforts to increase PBM transparency are putting greater attention on whether changes to rebates and compensation ultimately lower pharmacy costs.
As employers reconsider PBM relationships, SHARx warns switching vendors may not address the root incentives behind prescription drug costs.
SHARx argues that without tackling rebate-driven economics and PBM decision-making power, efforts to lower drug prices may have limited impact on patients.
As drugmakers implement 2026 price increases, SHARx argues that specialty pharmacy practices, not just list prices, often determine patient access and out-of-pocket costs.
